Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia
Anna Stanhewicz, PhD · NCT07715669
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- August 30, 2026
- Record last updated
- July 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. These changes have also been recorded in women who have depression. In the previous phase of this award, we found that women who had preeclampsia in pregnancy had changes in blood vessel health after pregnancy. We also found that if these women were taking a medicine to treat depression, their blood vessel health was normal. This could mean that treatment for depression can also increase blood vessel health in women who had preeclampsia. In this project we will study how changes in blood vessel health are related to preeclampsia and depression in women who have had both. We will also study how medicine to treat depression can improve blood vessel health after preeclampsia. We will do this by measuring how blood vessels work in women who have had preeclampsia compared to women who did not, and in women who have depression and women who do not. This will tell us more about why risk for depression and heart disease is higher in women who have had preeclampsia. It will also help us understand if medicine for depression can reduce cardiovascular disease risk after preeclampsia.
Being studied: Paroxetine Hydrochloride; Ascorbic acid (Vitamin C)
Conditions: Preeclampsia; Endothelial Function
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18-24 years old,
- 12 weeks - 5 years post pregnancy
- one of the following:
- history of a normal pregnancy with a current diagnosis of depression,
- history of a normal pregnancy without a current diagnosis of depression,
- history of a preeclamptic pregnancy with a current diagnosis of depression
- history of preeclamptic pregnancy without a current diagnosis of depression.
Exclusion Criteria
- history of cardiovascular, metabolic, and/or skin diseases
- current or history of tobacco/nicotine/ e-cigarette use
- history of gestational diabetes
- current antihypertensive or cholesterol-lowering medication
- currently pregnant
- allergy to materials used during the experiment (e.g. latex),
- known allergy to study drugs
- currently using SSRI medications
Recruiting US locations
University of Iowa
Iowa City, IA 52242-3521
Site contact: Anna Stanhewicz · 319-467-1732 · anna-stanhewicz@uiowa.edu
Study contacts (from the official record)
- Anna Reid-Stanhewicz, PHD · 319-467-1732 · anna-stanhewicz@uiowa.edu
Similar studies in Iowa
All mental health studies in Iowa →- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Des Moines, IA + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Iowa City, IA + 19 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
Motif Neurotech, Inc.
- Location
- Iowa City, IA + 2 other US sites
- Eligibility basics
- Ages 22–85
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- Waterloo, IA + 19 other US sites
- Eligibility basics
- Ages 18–75